Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Peer-Reviewed Evidence
HomeDrug RegistryCompareINJECTAPAP vs PRINCIPEN 250
Comparative Pharmacology

INJECTAPAP vs PRINCIPEN 250 Comparison

Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.

Clinical EssentialsPharmacokineticsSpecial PopulationsSafety & MonitoringPregnancy & LactationClinical Insights
Differential Analysis

INJECTAPAP vs PRINCIPEN '250'

Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.

View INJECTAPAP Monograph View PRINCIPEN '250' Monograph
INJECTAPAP
Non-Opioid Analgesic
Category C
PRINCIPEN '250'
Aminopenicillin Antibiotic
Category C
TL;DR — Key Differences
  • Drug class: INJECTAPAP is a Non-Opioid Analgesic; PRINCIPEN '250' is a Aminopenicillin Antibiotic.
  • Half-life: INJECTAPAP has a half-life of 2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.; PRINCIPEN '250' has 1.0-1.5 hours in normal renal function; prolongation in renal impairment requires dose adjustment.
  • No direct drug-drug interaction has been documented between INJECTAPAP and PRINCIPEN '250'.
  • Pregnancy: INJECTAPAP is rated Category C; PRINCIPEN '250' is rated Category C.

Last clinically reviewed: July 2026 · OpiCalc Medical Review Team

Clinical Essentials

INJECTAPAP
PRINCIPEN '250'
Mechanism of Action
INJECTAPAP

Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.

PRINCIPEN '250'

Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.

Indications
INJECTAPAP

Management of mild to moderate pain,Reduction of fever

PRINCIPEN '250'

Infections caused by susceptible strains of Gram-positive and Gram-negative bacteria, including respiratory tract infections, urinary tract infections, meningitis, septicemia, and endocarditis,Off-label: Prophylaxis for bacterial endocarditis in dental procedures, treatment of listeriosis

Standard Dosing
INJECTAPAP

1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.

PRINCIPEN '250'

250 mg orally every 6 hours

Direct Interaction
INJECTAPAP
No Direct Interaction
PRINCIPEN '250'
No Direct Interaction

Pharmacokinetics

INJECTAPAP
PRINCIPEN '250'
Half-Life
INJECTAPAP

2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.

PRINCIPEN '250'

1.0-1.5 hours in normal renal function; prolongation in renal impairment requires dose adjustment

Metabolism
INJECTAPAP

Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.

PRINCIPEN '250'

Ampicillin is primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion. Some hepatic metabolism occurs, but it is minimal.

Excretion
INJECTAPAP

Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).

PRINCIPEN '250'

Primarily renal (60-80% unchanged), with some biliary/fecal excretion (approximately 10-20%)

Protein Binding
INJECTAPAP

10-25% bound to albumin at therapeutic concentrations.

PRINCIPEN '250'

20-25% bound to serum albumin

VD (L/kg)
INJECTAPAP

0.8-1.0 L/kg; suggests distribution into total body water.

PRINCIPEN '250'

0.2-0.3 L/kg, indicating limited extravascular distribution

Bioavailability
INJECTAPAP

IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.

PRINCIPEN '250'

Oral: 25-40% (acid-labile, food reduces absorption)

Special Populations

INJECTAPAP
PRINCIPEN '250'
Renal Adjustments
INJECTAPAP

For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.

PRINCIPEN '250'

Cr Cl 10-50 m L/min: 250 mg every 12-24 hours; Cr Cl <10 m L/min: 250 mg every 24-48 hours

Hepatic Adjustments
INJECTAPAP

Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.

PRINCIPEN '250'

No dosage adjustment required for mild to moderate hepatic impairment. Severe impairment (Child-Pugh C): reduce dose by 50% or extend interval to every 12 hours

Pediatric Dosing
INJECTAPAP

For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.

PRINCIPEN '250'

Children >1 month: 12.5-25 mg/kg orally every 6 hours; maximum 4 g/day

Geriatric Dosing
INJECTAPAP

No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.

PRINCIPEN '250'

Monitor renal function; adjust dose based on Cr Cl as for adults with renal impairment. Avoid in elderly with Cr Cl <10 m L/min unless necessary.

Safety & Monitoring

INJECTAPAP
PRINCIPEN '250'
Black Box Warnings
INJECTAPAP
FDA Black Box Warning

Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.

PRINCIPEN '250'
FDA Black Box Warning

No FDA black box warning.

Warnings/Precautions
INJECTAPAP

Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products

PRINCIPEN '250'

Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported; contraindicated in patients with penicillin allergy.,Clostridium difficile-associated diarrhea (CDAD) can occur and may range in severity from mild diarrhea to fatal colitis.,Prolonged use may result in overgrowth of nonsusceptible organisms, including fungi; superinfection may occur.,Use with caution in patients with renal impairment; dosage adjustment may be necessary.,Cases of drug-induced hepatitis and cholestatic jaundice have been reported.

Contraindications
INJECTAPAP

Hypersensitivity to acetaminophen or any component of the formulation

PRINCIPEN '250'

History of allergic reaction to any penicillin,Infections caused by penicillinase-producing organisms

Adverse Reactions
INJECTAPAP
Data Pending
PRINCIPEN '250'
Data Pending
Food Interactions
INJECTAPAP

No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.

PRINCIPEN '250'

Food significantly reduces ampicillin absorption. Avoid taking with meals, dairy products, or acidic beverages (e.g., orange juice). Metal ions (calcium, iron, zinc) and antacids chelate ampicillin, reducing bioavailability. Alcohol does not directly interact but may increase risk of gastrointestinal upset.

Pregnancy & Lactation

INJECTAPAP
PRINCIPEN '250'
Teratogenic Risk
INJECTAPAP

FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.

PRINCIPEN '250'

FDA Pregnancy Category B. Animal studies show no fetal risk, but no adequate human studies in first trimester. No known teratogenicity; use during pregnancy only if clearly needed.

Lactation Summary
INJECTAPAP

Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.

PRINCIPEN '250'

Ampicillin is excreted in breast milk in low concentrations. M/P ratio approximately 0.1-0.2. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for diarrhea and candidiasis.

Pregnancy Dosing
INJECTAPAP

No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.

PRINCIPEN '250'

Increased plasma volume and renal clearance during pregnancy may reduce serum ampicillin concentrations. No routine dose adjustment recommended, but for serious infections, doses at the higher end of the usual range may be considered. Monitor therapeutic response.

Maternal Safety Status
INJECTAPAP
Category C
PRINCIPEN '250'
Category C

Clinical Insights

INJECTAPAP
PRINCIPEN '250'
Clinical Pearls
INJECTAPAP

Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.

PRINCIPEN '250'

Principen '250' (ampicillin) is a penicillinase-sensitive aminopenicillin with activity against Gram-positive cocci (except penicillinase-producing staphylococci) and some Gram-negative bacilli. Key pearls: (1) Administer on an empty stomach (1 hour before or 2 hours after meals) to enhance absorption; (2) Monitor for maculopapular rash, especially in patients with infectious mononucleosis or cytomegalovirus infection, where incidence approaches 70-100%; (3) Dose adjustment required in renal impairment (Cr Cl <30 m L/min); (4) Use caution in patients with history of hypersensitivity to penicillins or cephalosporins; (5) Not effective against penicillin-resistant Streptococcus pneumoniae; (6) Consider drug fever or serum sickness-like reactions as adverse effects.

Patient Counseling
INJECTAPAP

Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.

PRINCIPEN '250'

Take this medication exactly as prescribed, at evenly spaced times, and finish the full course even if you feel better.,Take on an empty stomach, at least 1 hour before or 2 hours after meals, with a full glass of water.,Do not take with antacids, laxatives, or fruit juices, as they may reduce absorption.,Contact your doctor immediately if you develop a skin rash, hives, difficulty breathing, or swelling of the face, lips, or tongue.,Diarrhea is common; do not treat with anti-diarrhea medications without consulting your doctor, as it may indicate a more serious condition.,Inform your doctor if you are pregnant, breastfeeding, or have a history of kidney disease, asthma, or allergic reactions to any antibiotic.,This drug may reduce the effectiveness of oral contraceptives; use an additional barrier method during treatment.

Safety Verification

Known Interactions

INJECTAPAP Risks

No interactions on record

PRINCIPEN '250' Risks

No interactions on record

Compare Alternatives

Related Drug Comparisons

Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.

INJECTAPAP vs ACEPHENNon-Opioid Analgesic
PRINCIPEN '250' vs ACEPHENNon-Opioid Analgesic
INJECTAPAP vs OFIRMEVNon-opioid Analgesic
PRINCIPEN '250' vs OFIRMEVNon-opioid Analgesic
INJECTAPAP vs PRINCIPENAminopenicillin Antibiotic
PRINCIPEN '250' vs PRINCIPENAminopenicillin Antibiotic
INJECTAPAP vs PRINCIPEN '125'Aminopenicillin Antibiotic
PRINCIPEN '250' vs PRINCIPEN '125'Aminopenicillin Antibiotic
INJECTAPAP vs PRINCIPEN '500'Aminopenicillin Antibiotic
Clinical Q&A

Frequently Asked Questions

Common clinical questions about INJECTAPAP vs PRINCIPEN '250', answered by our medical review team.

1. What is the main difference between INJECTAPAP and PRINCIPEN '250'?

INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. PRINCIPEN '250' is a Aminopenicillin Antibiotic that works by Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.

2. Which is stronger: INJECTAPAP or PRINCIPEN '250'?

Potency comparisons between INJECTAPAP and PRINCIPEN '250' depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.

3. What is the standard dosing for INJECTAPAP vs PRINCIPEN '250'?

The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. The standard adult dose of PRINCIPEN '250' is: 250 mg orally every 6 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.

4. Can you take INJECTAPAP and PRINCIPEN '250' together?

No direct drug-drug interaction has been formally documented between INJECTAPAP and PRINCIPEN '250' in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.

5. Are INJECTAPAP and PRINCIPEN '250' safe during pregnancy?

The maternal-fetal safety profiles differ. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. PRINCIPEN '250' is classified as Category C. FDA Pregnancy Category B. Animal studies show no fetal risk, but no adequate human studies in first trimester. No known teratogenicity; use during pregnancy only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.